Press releases

Company's new lead system reduces implant size of the world's smallest and thinnest high-energy devices

Authors identify important differences between drug-eluting stent brands

Highlights of the week's events include late-breaking trial presentations from the MADIT II clinical trial and the ALTITUDE Clinical Science Program

Data from landmark trial provide important insight for physicians in treating heart attack patients

A live webcast and replay of the May 12 conference session will be available. Learn how to tune in.

We're off to a good start on the year," said Jim Tobin, President and Chief Executive Officer

Boston Scientific today announced special items that will reduce its GAAP earnings for the first quarter

Company will webcast its April 21 call. Learn how to tune in.

Upheld District Court's decision that JNJ's Bx Velocity and Cypher Stent Systems infringe Boston Scientific's patent

Legislation will help evaluate the current state of chronic pain care in the United States

Three-year results and two-year pooled analysis presented at ACC demonstrate continued positive outcomes for both PROMUS® and TAXUS® Stents

Analysis of economic and quality of life outcomes are based on one-year data from landmark SYNTAX trial

Presentations to include additional analyses of one-year data from the landmark SYNTAX study

Upgrade follows the Moody's actions of March 12, when it raised Company's outlook to stable from negative

iCross™ designed to improve the deliverability of Company's market-leading intravascular ultrasound (IVUS) technology

Rating agency notes that Company has been able to retain market share in the DES arena while rebuilding its CRM presence with new product launches

A live webcast of the March 17 conference session will be available.

Legislation to evaluate the current state of chronic pain care will now move to consideration by the full House

Japanese patients now have access to second-generation drug-eluting stent

Joel Fleishman to retire from Board

Adjustments reflected in the Company's Form 10-K to be filed tomorrow

Data show comparable safety for complex patients treated with TAXUS® Express2™ Stents and bypass surgery

Journal of American College of Cardiology publishes positive ATLAS clinical data

PLATINUM clinical program to evaluate PROMUS™ Element™ Platinum Chromium Stent

Q4 adjusted results in line with expectations; Company well positioned for 2009 and beyond

Product is Japan's first second-generation drug-eluting stent

Agreement stops all litigation in interventional cardiology and endovascular repair

Provides Company the opportunity to supply therapies for VA patients at risk of sudden cardiac death and bradycardia arrhythmias

Court found patent to be invalid as obvious over the prior art; Company considering its options for challenging the decision

Company will webcast its January 29 conference call

A live webcast of the January 14 presentation will be available

Acquisition demonstrates Company's commitment to innovation in drug-eluting stent technology

First patient enrolled in Carotid WALLSTENT® Endoprosthesis registry

First low-profile, pre-mounted stent approved specifically for use in renal arteries

A live webcast of the December 2, 2008 session will be available

New design provides more options for treating patients with complex lesions

Boston Scientific Corporation (NYSE: BSX) today welcomed passage of legislation to help active members of the U.S. armed forces and service...

Confirms clinical value and cost-effectiveness of spinal cord stimulation

Leading carotid stent in Europe and other international markets now available in the United States

"For the second consecutive quarter, we maintained our strong U.S. DES market share leadership," said President and CEO Jim Tobin

Landmark trial provides new insight for physicians

Outcomes from the study of 22,000 patients with coronary artery disease continues to show impressive safety and efficacy data

New SYNTAX Score shows similar safety and efficacy outcomes for two thirds of study's patients

Company moves up Q3 earnings release date

TAXUS® Atom™ in more than 500 accounts Company opening new PROMUS™ accounts

Joint efforts will focus on intravascular ultrasound (IVUS)

Thursday and Friday of last week saw continued heavy trading in Boston Scientific's (NYSE: BSX) stock. As anticipated in the Company's October 9th...

Two-year pooled ARRIVE data showed the TAXUS Stent reduced clinical restenosis in patients with diabetes as effectively as in patients without diabetes

New coronary stent features thin struts designed for more uniform drug delivery

TAXUS Liberte drug eluting stent, launched in Europe and other international markets in 2005, to launch in U.S. next month

Company will also present results from the ARRIVE diabetic subset analysis, the ATLAS Workhorse and Direct Stenting trials and ATLAS data on small vessels and long lesions

The recent turmoil in the financial markets and bankruptcy of Lehman Brothers triggered automatic share selling

Company to discuss these and other issues on its third quarter earnings call on October 23 at 8:00 a.m.

PERSEUS clinical program to evaluate TAXUS® Element™ Platinum Chromium Stent

Judgment against Company entered in a patent case filed in 1997; Company to appeal

Company also announces FDA approval of TAXUS® Express2™ Stent System for treatment of in-stent restenosis

A live webcast and replay of the September 25 session will be available

Boston Scientific Corporation (NYSE: BSX) announced today a decision by the United States District Court in Delaware. The case involves a patent...

A live webcast and replay of the Tuesday, September 16 session will be available

Company announced positive one-year results from the world's largest post-approval, prospective registry for a single drug-eluting stent (DES)

Overall results demonstrated no statistically significant differences between PCI and CABG in rates of death or myocardial infarction (MI)

Boston Scientific obligation reduced from $250 to $19 million; Company to appeal remaining award

Company to present data from landmark SYNTAX clinical trial

"We were pleased with the quarter, especially with our expense management and working capital initiatives,” said CEO Jim Tobin.

Boston Scientific only company to offer choice of two distinct drugs on separate drug-eluting stent platforms

A live webcast and replay of the July 22 conference call will be available

Legislation would help service veterans and the active armed forces better manage the challenges of chronic pain

Transactions further Company's plans to focus on core businesses and increase shareholder value

Fitch also reaffirmed the Company's long-term credit rating of BB+

A live webcast and replay of the June 11 session will be available

Company announces management changes and further organizational consolidation

Environmentally focused improvements are hallmark of renovations to Endosurgery headquarters

Transaction follows the definitive agreement announced on April 16

Boston Scientific Corporation (NYSE: BSX) today announced that a U.S. District Court jury in Marshall, Texas has reached a verdict in a patent...

Boston Scientific Corporation (NYSE: BSX) today announced results from an international, multi-center patient registry documenting...

Boston Scientific Corporation (NYSE: BSX) today announced the launch of its FilterWire EZ™ Embolic Protection System in a new 2.25 - 3.5 mm size,...

Boston Scientific Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration (FDA) approval of its ACUITY® Spiral left ventricular...

Boston Scientific Corporation (NYSE: BSX) today announced that results from an international, multi-center patient registry documenting the safety...

Boston Scientific Corporation (NYSE: BSX) today announced a new clinical science initiative, ALTITUDE, which will analyze data(1) from the...

Boston Scientific Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration (FDA) approval of its COGNIS™ cardiac...

Boston Scientific Corporation (NYSE: BSX) today announced results from an analysis of nearly 7,500 patients from its TAXUS...

Boston Scientific Corporation (NYSE: BSX) today welcomed two-year results from the SPIRIT III clinical trial, which continue to...

Boston Scientific Corporation (NYSE: BSX) and the International Diabetes Federation (IDF) today announced that Boston...

Boston Scientific Corporation (NYSE: BSX) announced today that the Canadian Federal Court has issued judgment in a lawsuit in which Johnson & Johnson...

Boston Scientific Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration (FDA) approval of its ALTRUA™ family of pacemakers....

Boston Scientific Corporation (NYSE: BSX) today announced CE Mark approval and market launch of its ALTRUA™ family of pacemakers. ALTRUA is Boston...

Boston Scientific Corporation (NYSE: BSX) announced today that a World Intellectual Property Organization (WIPO) arbitration panel has issued its...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Deutsche Bank Health Care Conference, which is being held May 5-7 in...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Morgan Stanley Global Healthcare Unplugged Conference, which is being...

Boston Scientific Corporation (NYSE: BSX) today announced completion of enrollment in the Multicenter Automatic Defibrillator Implantation Trial...

Boston Scientific Corporation (NYSE: BSX) today announced that it has been named U.S. Healthcare Supplier of the Year in the GHXcellence Awards...

Boston Scientific Corporation (NYSE: BSX) today announced financial results for the first quarter ended March 31, 2008, as well as guidance for...

Boston Scientific Corporation (NYSE: BSX) today announced that it has received approval for the sale of its TAXUS® Liberte® paclitaxel-eluting...

Boston Scientific Corporation (NYSE: BSX) and CryoCor, Inc. (NASDAQ: CRYO) today announced the signing of a definitive...

Boston Scientific Corporation (NYSE: BSX) and Surgi-Vision, Inc., a privately held company, today announced a licensing and...

Boston Scientific Corporation (NYSE: BSX) today announced Japanese Ministry of Health, Labor and Welfare (MHLW) approval of its ACUITY® Steerable...

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the first quarter ended March 31,...

Boston Scientific Corporation (NYSE: BSX) today announced the appointment of Timothy Pratt as its new General Counsel. Pratt is a nationally...

Boston Scientific Corporation (NYSE: BSX) today announced that United States District Judge Sarah Evans Barker, Indianapolis, dismissed...

Boston Scientific Corporation (NYSE: BSX) today announced results from a pooled analysis of patients from its TAXUS IV and TAXUS...